Literature DB >> 8157363

Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride.

D Rideout1, A Bustamante, J Patel.   

Abstract

Cationic phosphonium salts are interesting because they inhibit the proliferation of carcinoma cells more than untransformed epithelial cells in vitro. This differential anti-proliferative effect has been used to identify phosphonium salts and other lipophilic cations that later demonstrated effects in animals. Using 6 carcinoma-derived and 2 untransformed epithelial cell lines, tetraphenylphosphonium chloride (TPP) and other cationic aryl phosphonium salts (CAPS) demonstrated a growth inhibition pattern similar to that of cation rhodamine 123, suggesting that CAPS may inhibit mitochondrial function. We tested this hypothesis for the effect of phosphonium salt TPP on FaDu human hypopharyngeal carcinoma cells. TPP inhibited the proliferation of FaDu carcinoma cells at submicromolar concentrations. Uptake of 3H-TPP by FaDu cells was partially inhibited in medium containing high K+ and fully inhibited by valinomycin in this medium, indicating that TPP accumulates preferentially in mitochondria, and to a lesser extent in the cytoplasm. FaDu cells exposed to TPP exhibited damage to mitochondrial inner membranes, reduced ATP/ADP ratios, decreased oxygen uptake rates and decreased mitochondrial membrane potentials. The treated cells secreted lactate more rapidly than untreated controls and exhibited hypersensitivity to 2-deoxyglucose, an inhibitor of glycolysis. TPP's antimitochondrial effects apparently enhance cytoplasmic glycolysis. In conclusion, TPP inhibits FaDu carcinoma cell growth by inhibiting mitochondrial respiration and ATP synthesis. Cationic phosphonium salts that inhibit carcinoma cell growth through antimitochondrial effects might be used to treat solid tumors without the risk of secondary tumors associated with agents affecting nuclear DNA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157363     DOI: 10.1002/ijc.2910570220

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 2.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622

3.  Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.

Authors:  Brian Cunniff; Kira Benson; Jason Stumpff; Kheng Newick; Paul Held; Douglas Taatjes; Joy Joseph; Balaraman Kalyanaraman; Nicholas H Heintz
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

4.  Phosphonium lipocations as antiparasitic agents.

Authors:  Timothy E Long; Xiao Lu; Melina Galizzi; Roberto Docampo; Jiri Gut; Philip J Rosenthal
Journal:  Bioorg Med Chem Lett       Date:  2012-02-23       Impact factor: 2.823

5.  Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity.

Authors:  Melissa Millard; Divya Pathania; Yumna Shabaik; Laleh Taheri; Jinxia Deng; Nouri Neamati
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

6.  Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance.

Authors:  Xue Han; Ruijuan Su; Xiuqing Huang; Yingli Wang; Xiao Kuang; Shuang Zhou; Hongzhuo Liu
Journal:  Asian J Pharm Sci       Date:  2018-09-18       Impact factor: 6.598

7.  Synthesis and Antiproliferative Activity of Triphenylphosphonium Derivatives of Natural Allylpolyalkoxybenzenes.

Authors:  Dmitry V Tsyganov; Alexander V Samet; Eugenia A Silyanova; Vladimir I Ushkarov; Alexander E Varakutin; Natalia B Chernysheva; Roman N Chuprov-Netochin; Andrey A Khomutov; Anna S Volkova; Sergey V Leonov; Marina N Semenova; Victor V Semenov
Journal:  ACS Omega       Date:  2022-01-24

8.  Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells.

Authors:  Christophe J De Saedeleer; Tamara Copetti; Paolo E Porporato; Julien Verrax; Olivier Feron; Pierre Sonveaux
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

Review 9.  Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents.

Authors:  Josephine S Modica-Napolitano; Volkmar Weissig
Journal:  Int J Mol Sci       Date:  2015-07-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.